Healthcare -
Biotechnology - NASDAQ - US
$ 2.72
3.03 %
$ 2.4 B
Market Cap
-4.77
P/E
1. INTRINSIC VALUE
Balance Sheet
ImmunityBio, Inc.
| Current Assets | 185 M |
| Cash & Short-Term Investments | 150 M |
| Receivables | 2.65 M |
| Other Current Assets | 32.1 M |
| Non-Current Assets | 198 M |
| Long-Term Investments | 0 |
| PP&E | 170 M |
| Other Non-Current Assets | 27.9 M |
| Current Liabilities | 54.9 M |
| Accounts Payable | 6.72 M |
| Short-Term Debt | 7.47 M |
| Other Current Liabilities | 40.8 M |
| Non-Current Liabilities | 816 M |
| Long-Term Debt | 497 M |
| Other Non-Current Liabilities | 319 M |
EFFICIENCY
Earnings Waterfall
ImmunityBio, Inc.
| Revenue | 14.7 M |
| Cost Of Revenue | 0 |
| Gross Profit | -2.81 M |
| Operating Expenses | 359 M |
| Operating Income | -344 M |
| Other Expenses | 69.5 M |
| Net Income | -414 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
ImmunityBio, Inc.
| Net Income | -414 M |
| Depreciation & Amortization | 17.6 M |
| Capital Expenditures | -6.89 M |
| Stock-Based Compensation | 34.4 M |
| Change in Working Capital | -19.4 M |
| Others | -10.2 M |
| Free Cash Flow | -398 M |
Wall Street Analysts Price Targets
ImmunityBio, Inc.
Wall Street analysts predict an average 1-year price target for IBRX of $6 , with forecasts ranging from
a
low of
$6 to a high of $6 .
IBRX Lowest Price Target
Wall Street Target
6 USD
120.59%
IBRX Average Price Target
Wall Street Target
6 USD
120.59%
IBRX Highest Price Target
Wall Street Target
6 USD
120.59%
4. DIVIDEND
ANALYSIS
IBRX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
ImmunityBio, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze
ImmunityBio, Inc.'s Anktiva shows promise for bladder cancer, but faces FDA setbacks and a rocky approval path. Peak sales for Anktiva's indications could reach $900 million by 2028, implying a 73% upside, but this is far from guaranteed. The company's lymphopenia treatment would face zero competition and would provide a larger addressable market.
seekingalpha.com
- 1 month ago
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy. This data supports that reversal of lymphopenia, a well-established root cause of early mortality in patients with cancer across all tumor types, correlates with significant improved survival. While anemia and neutropenia have long been addressed by agents like Epogen and Neupogen, no therapy has ever.
businesswire.com
- 1 month ago
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the use of its Cancer BioShield™ platform, anchored by ANKTIVA® (nogapendekin alfa inbakicept-pmln), to treat lymphopenia in adult patients with refractory or relapsed solid tumors independent of tumor type who have progressed after first-line standard-of-care treatment, chemotherap.
businesswire.com
- 1 month ago
ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East
CULVER CITY, Calif. & RIYADH, Saudi Arabia--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the signing of a strategic Memorandum of Understanding (MOU) with the Ministry of Investment of Saudi Arabia (MISA), King Faisal Specialist Hospital & Research Centre (KFSHRC), and King Abdullah International Medical Research Center (KAIMRC). This multi-party collaboration will introduce the FDA-approved Cancer BioShield platform to Saudi Arabia and.
businesswire.com
- 1 month ago
ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade
ImmunityBio (IBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 2 months ago
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.20 per share a year ago.
zacks.com
- 2 months ago
ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) in January 2025, as well as its financial results for the first-quarter ended March 31, 2025. With the issuance of the permanent J-code (J9028) in January 2025, ImmunityBio has seen increased sales momentum supporting a trend of increases month-over-month as well as quarter-over-quarter, with March.
businesswire.com
- 2 months ago
ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA
ImmunityBio, Inc.'s sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a similar indication. The market reacted negatively, dropping IBRX shares to around $2.00, but the trading volume was not extremely high. Despite the setback, I maintain a conviction level of 3 out of 5 for IBRX, focusing on potential long-term gains and upcoming catalysts.
seekingalpha.com
- 2 months ago
ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug
ImmunityBio, Inc. IBRX on Monday received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for the indication of papillary disease.
benzinga.com
- 2 months ago
ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for the indication of papillary disease. This RTF letter was received despite reaching unanimous.
businesswire.com
- 2 months ago
ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
ImmunityBio (IBRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
- 2 months ago
ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings.
seekingalpha.com
- 2 months ago
8. Profile
Summary
ImmunityBio, Inc. IBRX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 2.4 B
Dividend Yield
0.00%
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Contact
3530 John Hopkins Court, San Diego, CA, 92121
https://immunitybio.com
IPO
Date
July 28, 2015
Employees
671
Officers
Mr. Jason R. Liljestrom J.D.
General Counsel & Corporate Secretary
Dr. Leonard S. Sender M.D.
Chief Medical Officer of Liquid Tumors & Cell Therapy
Mr. David C. Sachs
Chief Financial Officer
Dr. Barry J. Simon M.D.
Chief Corporate Affairs Officer & Director
Dr. Enrique Diloné Ph.D., RAC
Chief Technology Officer
Dr. Sandeep K. Reddy M.D.
Chief Medical Officer
Mr. Richard Gerald Adcock
President, Chief Executive Officer & Director
Ms. Sarah Singleton
Chief Communications Officer & Head of Patient Advocacy
Ms. Regan J. Lauer
Chief Accounting Officer
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.
Executive Chairman of the Board and Global Chief Scientific & Medical Officer